Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation

Nephrology

Volumn 8, Issue 4, 2003, Pages 212-216

  Chow, Fiona Y F ^a   Polkinghorne, Kevan ^a   Saunder, Alan ^a   Kerr, Peter G ^a   Atkins, Robert C ^a   Chadban, Steven J ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Acute rejection; Basiliximab; Infectious complications; OKT3; Simultaneous pancreas kidney transplantation

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID; OKT 3; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT INFECTION; GRAFT SURVIVAL; HUMAN; INCIDENCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MUROMONAB-CD3; PANCREAS TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES;

EID: 0042664085     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2003.00158.x     Document Type: Article

References (20)

1. Sollinger HW, Odorico JS, Knectle SJ et al. Experience with 500 simultaneous pancreas-kidney transplants. Ann. Surg. 1998; 228: 284-96.
2. Sutherland DE, Gruessner AC. Pancreas Transplantation in the United States as Reported to the United Network for Organ Sharing (UNOS) and analyzed by the International Pancreas Transplant Registry. Clin. Transpl. 1995; 1: 47-69.
3. Norman DJ, Kahana L, Stuart FP et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44-50.
4. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 1995; 60: 1220-4.
5. Hariharan S, Alexander JW, Schroeder TJ et al. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporin era. Clin. Transplantation 1996; 10: 186-90.
6. Cantarovich D, Karam G, Giral-Classe M et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int. 1998; 54: 1351-6.
7. Abramowicz D, Pradier O, Marchant A et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992; 339: 777-8.
8. Oh CS, Stratta RJ, Fox BC et al. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1998; 45: 68-73.
9. Jamil B, Nicholls K, Becker GJ et al. Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 1999; 68: 1597-603.
10. Soulillou JP, Cantarovich D, Le Mauff B et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N. Engl. J. Med. 1990; 322: 1175-82.
11. Nashan B, Moore R, Amlot P et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-8.
12. Vincenti F, Kirkman R, Light S et al. Interleukin-2 receptor blockade with dacluzimab to prevent acute rejection in renal transplantation. N. Engl. J. Med. 1998; 338: 161-5.
13. Ponticelli C, Yussim A, Cambi V et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261-7.
14. Cantarovich D, Le Mauff B, Hourmant M et al. Prevention of acute rejection episodes with an interleukin-2 receptor monoclonal antibody. 1. Results after combined pancreas and kidney transplantation. Transplantation 1994; 57: 198-203.
15. Rasaiah SB, Light JA, Sasaki TM et al. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression. Clin. Transplantation 2000; 14: 409-12.
16. Hesse UJ, Troisi R, Jacobs B et al. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin. Transplantation 2000; 14: 340-4.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 1987; 317: 1049-54.
19. Lowance D, Neumayer HH, Legendre CM et al. Valaciclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valaciclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N. Engl. J. Med. 1999; 340: 1462-70.
20. Newell KA, Bruce DS, Cronin DC et al. Comparison of pancreas transplantation with portal venous and enteric exocrine drainage to the standard technique utilizing bladder drainage of exocrine secretions. Transplantation 1996; 62: 1353-6.